Sep 2026· Head and neck tumors (HNT)· Vol 16, pp. 99-108· 0 citations· 5 references
TL;DR
The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.
Abstract
The article presents a clinical case of treating stage IV anaplastic thyroid cancer with a V600E mutation in the BRAF gene and distant metastasis (including metastases to the right ventricle of the heart and the right adrenal gland). At the first stage, targeted therapy (dabrafenib + trametinib) was performed, which allowed achieving pronounced clinico-metabolic regression and performing radical multi-stage surgical treatment. Subsequently, with the development of drug resistance and the detection of high expression of programmed cell death 1 ligand (PD-L1) (Combined Positive Score (CPS) – the ratio of the number of PD-L1-positive cells to the total number of tumor cells = 100), immunotargeted therapy with pembrolizumab in combination with lenvatinib was prescribed, resulting in a partial metabolic response. Despite the subsequent disease progression, overall survival from the time of diagnosis was 46 months. The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.
The optimal sequencing of immunotherapy and radiotherapy in non-small cell lung cancer (NSCLC) remains unclear. The present study reports a case of advanced lung adenocarcinoma (cT4N2bM1a, stage IVa) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 90% and TP53 mutation. The patient received first-lin...
Qi Zhou, Bo Yang, Hong-Yi Cai et al.· Oncology Letters· 0 citations
BACKGROUND
Chemotherapy has been always considered scarcely or completely ineffective in the treatment of metastatic and progressive MTC.
CASE REPORT
We report the case of a 45-year-old man who underwent total thyroidectomy and lymphadenectomy in May 2023 for bilateral MTC with extrathyroidal extension and 2/23 metas...
M. Trevisan, Giulia Puxeddu, Martina Violati et al.· European Thyroid Journal· 0 citations
Introduction.
Metastatic colorectal cancer remains one of the major challenges in modern oncology due to its high incidence, frequent diagnosis at advanced stages, and the limited efficacy of standard lines of systemic therapy. In recent years, molecular genetic profiling of tumors has become increasingly important,...
A. B. Sunyaykin, V. Apanasevich, S. S. Startsev et al.· Clinical Case in Oncology· 0 citations
Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy...
F. A. Francis, N. Kannur, Vijay Pillai et al.· Thyroid Research and Practic...· 0 citations
Introduction
. Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. BRAF mutations (predominantly V600E) occur in 5–10% of mCRC cases and are associated with an aggressive disease phenotype, poor response to conventional chemotherapy, and dismal prognosis. In the Russian...
A. S. Fattakhova, S. V. Cheporov, N. P. Shiryaev· Medical alphabet· 0 citations
Anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK-positive NSCLC) is a molecularly defined subtype of lung cancer in which the optimal sequencing of systemic therapy is essential for achieving long-term disease control. Progression involving the central nervous system (CNS) represents a particular cli...
A. Bekisheva, G. Akylzhanova, F. Olzhayev· BULLETIN of the L.N. Gumilyo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.